



FIGURE 1



B.

	Active Run-in			5- per protocol reduction attempts								Maintenance (no further reduction)			
	8 weeks			32 weeks								16 weeks			
	↑	↑	○	↑	○	○	○	○	○	○	○	↑			
Weeks	24	28	32	36	40	44	48	52	56	60	64	68	72	76	80
Visits	V13	V14	V15	V16	V17	V18	V19	V20	V21	V22	V23	V24	V25	V26	V27
				☎		☎		☎		☎		☎		☎	EOS
Days	168	196	224	252	280	308	336	364	392	420	448	476	504	532	560

EOS End of ANDHI IP Substudy
○ Per protocol background reduction attempts based on asthma control
↑ Open label benralizumab dosed
☎ Telephone visits

FIGURE 2

Reduction in annualised AER for patients in the benralizumab group versus patients in the placebo group.

AER=asthma exacerbation rate; CI=confidence interval.

FIGURE 3





FIGURE 4




FIGURE 5**(A) Highest Ranked Symptom/Impairment****(B) Average of Top 3 Ranked Symptoms/Impairments**

FIGURE 6



ACQ-6=Asthma Control Questionnaire 6; AER=Asthma Exacerbation Rate; EOS=eosinophil count at screening; FEV₁=forced expiratory volume in 1 second; FVC=forced vital capacity; MMRM=mixed-effect model repeated measure; OCS=oral corticosteroid; SGRQ=St. George's Respiratory Questionnaire.

FIGURE 7






FIGURE 8

FIGURE 9

^aComprehensive response defined as achieving a clinically meaningful improvement in SNOT-22 of ≥ -8.9 units and clinically meaningful results in 4 additional criteria (AER=0 exacerbations; SGRQ change ≤ -4 units; FEV₁ improvement ≥ 200 mL; and ACQ-6 change ≤ -0.5).